Researchers have identified a promising approach to combat sarcopenia in aging mice by targeting the ghrelin receptor (GHSR-1a) rather than the hormone itself. In a study published in Aging Cell, knocking out the GHSR-1a receptor demonstrated significant improvements in muscle function and mitochondrial health, highlighting its potential as a therapeutic target for age-related muscle decline.

The study revealed that GHSR-1a knockout mice exhibited reduced muscle fatigue and enhanced mitochondrial function compared to their wild-type counterparts. Specifically, these knockout mice could run nearly 30% longer at 24 months and showed a 45% increase in endurance by 28 months. Additionally, the knockout mice maintained higher levels of PGC-1α, a key regulator of mitochondrial biogenesis, and demonstrated improved mitophagy, which is crucial for cellular health. However, it is noteworthy that while muscle function improved, overall lifespan remained unchanged between the knockout and wild-type groups.

The findings suggest that targeting the ghrelin receptor could shift the current paradigm in sarcopenia research, offering a more translatable strategy for clinical applications compared to directly manipulating ghrelin levels. This receptor-focused approach may accelerate drug development timelines for therapies aimed at enhancing muscle strength and function in the elderly, though it does not address longevity directly. Future research may explore optimizing receptor inhibition to maximize benefits while investigating the underlying mechanisms that could lead to improved healthspan without compromising lifespan.

Source: lifespan.io